Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2475-2484

  Ivanova, Jasmina I ^a   Birnbaum, Howard G ^a   Kidolezi, Yohanne ^a   Subramanian, Ganesh ^a   Khan, Sajjad A ^b,c,d   Stensland, Michael D ^d,e  

^a ANALYSIS GROUP   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c Children's Resource Group   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e Agile Outcomes Research Inc   (United States)

Author keywords

Costs; Major depression; Treatment resistant depression

Indexed keywords

FLUOXETINE; GENERIC DRUG;

ABSENTEEISM; ADULT; ALCOHOL ABUSE; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DRUG ABUSE; ELECTROCONVULSIVE THERAPY; EMPLOYEE; FEMALE; FIBROMYALGIA; HEALTH CARE COST; HUMAN; IMPULSE CONTROL DISORDER; INSOMNIA; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR DEPRESSION; MALE; MCNEMAR TEST; MIGRAINE; OBESITY; OSTEOARTHRITIS; OUTPATIENT; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; TREATMENT DURATION; WILCOXON SIGNED RANKS TEST;

ABSENTEEISM; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; EMPLOYER HEALTH COSTS; EMPLOYMENT; FEMALE; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77956761828     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.517716     Document Type: Article

References (20)

1. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-1475
2. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006;163:1561-1568
3. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-418
4. Greenberg P, Corey-Lisle PK, Birnbaum HG, et al. Economic implications of treatment-resistant depression among employees. PharmacoEconomics 2004;22:363-373
5. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
6. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
7. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58:23-29
8. Souery D, Amsterdam J, de Montigny C, et al. Treatment-resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91
9. Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data 'signature' and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002;63:717-726
10. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63: 963-971
11. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659
12. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341-347
13. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54
14. Health Affairs. Press release: number of Americans with job-based health benefits grew through early 2001, despite higher benefit costs. January 8, 2002. Available at: http://www.healthaffairs.org/press/janfeb0202.htm [Last accessed June 17, 2002]
15. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 2nd edn, 2000. Available at http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx? file¼ MDD2e-Inactivated-04-16-109 [Last accessed 25 June 2009]
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
17. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1075-1079
18. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917
19. Gibson TB, Jing Y, Carls GS, et al. The cost burden of treatment resistance in patients with depression. Value Health 2009;12:A177
20. Pincus HA, Pettit AR. The societal costs of chronic major depression. J Clin Psychiatry 2001;62(Suppl. 6):5-9